Renal cell cancer: is immunotherapy dead?
Wagstaff
J
J
South West Wales Cancer Institute & the University of Wales Swansea, School of Medicine, Singleton Hospital, Swansea, UK.
D019496:Cancer Vaccines / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007372:Interferons / Q000276:immunology / Q000627:therapeutic use; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology / Q000627:therapeutic use
D019496:Cancer Vaccines; D007376:Interleukin-2; D042461:Vascular Endothelial Growth Factor A; D007372:Interferons